These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 17323509

  • 1. Editorial comment: tenofovir-related nephrotoxicity--who's at risk?
    Gupta Samir K.
    AIDS Read; 2007 Feb; 17(2):102-3. PubMed ID: 17323509
    [No Abstract] [Full Text] [Related]

  • 2. Editorial comment: mixing tenofovir with other nephrotoxins--how safe is this?
    Gupta SK.
    AIDS Read; 2009 Feb; 19(6):246. PubMed ID: 19642244
    [No Abstract] [Full Text] [Related]

  • 3. Editorial comment: tenofovir nephrotoxicity--the disconnect between clinical trials and real-world practice.
    Atta MG, Fine DM.
    AIDS Read; 2009 Mar; 19(3):118-9. PubMed ID: 19334329
    [No Abstract] [Full Text] [Related]

  • 4. Tenofovir and changes in renal function.
    Gupta SK.
    Clin Infect Dis; 2005 Aug 15; 41(4):570-1; author reply 571. PubMed ID: 16028175
    [No Abstract] [Full Text] [Related]

  • 5. Tenofovir-induced nephrotoxicity: myths and facts.
    Gupta A, Bugeja A, Kirpalani D.
    Saudi J Kidney Dis Transpl; 2012 Jan 15; 23(1):148-9. PubMed ID: 22237241
    [No Abstract] [Full Text] [Related]

  • 6. Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.
    Psevdos G, Gonzalez E, Sharp V.
    AIDS Read; 2009 Jan 15; 19(6):245-8. PubMed ID: 19642243
    [Abstract] [Full Text] [Related]

  • 7. Hypokalemia in HIV patients on tenofovir.
    Cirino CM, Kan VL.
    AIDS; 2006 Aug 01; 20(12):1671-3. PubMed ID: 16868451
    [Abstract] [Full Text] [Related]

  • 8. Renal safety of tenofovir disoproxil fumarate.
    Sax PE, Gallant JE, Klotman PE.
    AIDS Read; 2007 Feb 01; 17(2):90-2, 99-104, C3. PubMed ID: 17323508
    [Abstract] [Full Text] [Related]

  • 9. Meeting notes from ICAAC. Tenofovir + ddI: a combination to avoid.
    Sax PE.
    AIDS Clin Care; 2005 Jan 01; 17(1):6-7. PubMed ID: 15717372
    [No Abstract] [Full Text] [Related]

  • 10. HIV therapy may be given safely in resource-limited settings without routine laboratory monitoring.
    AIDS Patient Care STDS; 2009 Aug 01; 23(8):680-1. PubMed ID: 19694040
    [No Abstract] [Full Text] [Related]

  • 11. Effect of tenofovir on renal glomerular and tubular function.
    Fux CA, Christen A, Zgraggen S, Mohaupt MG, Furrer H.
    AIDS; 2007 Jul 11; 21(11):1483-5. PubMed ID: 17589197
    [Abstract] [Full Text] [Related]

  • 12. Tenofovir nephrotoxicity: focusing research questions and putting them into clinical context.
    Szczech LA.
    J Infect Dis; 2008 Jan 01; 197(1):7-9. PubMed ID: 18171278
    [No Abstract] [Full Text] [Related]

  • 13. Improvement in chronic renal impairment following the discontinuation of tenofovir in two HIV-infected patients.
    Gracey D, Post J, MacLeod C, McKenzie P.
    Nephrology (Carlton); 2011 May 01; 16(4):453-5. PubMed ID: 21518120
    [No Abstract] [Full Text] [Related]

  • 14. Estimating renal function in patients on tenofovir disoproxil fumarate: suggestions for safer use.
    Winston J, Shepp DH.
    HIV Med; 2006 Oct 01; 7(7):484-5. PubMed ID: 16925736
    [No Abstract] [Full Text] [Related]

  • 15. Editorial comment: tenofovir nephrotoxicity--vigilance required.
    Fine DM.
    AIDS Read; 2005 Jul 01; 15(7):362-3. PubMed ID: 16044578
    [No Abstract] [Full Text] [Related]

  • 16. [First line therapy. Tenofovir DF/emtricitabine--the potent backbone].
    MMW Fortschr Med; 2008 Apr 28; 150 Spec No 1():12-4. PubMed ID: 19024908
    [No Abstract] [Full Text] [Related]

  • 17. Tenofovir and didanosine: a dangerous liaison.
    Waters L, Maitland D, Moyle GJ.
    AIDS Read; 2005 Aug 28; 15(8):403-6, 413. PubMed ID: 16110555
    [No Abstract] [Full Text] [Related]

  • 18. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy.
    Côté HC, Magil AB, Harris M, Scarth BJ, Gadawski I, Wang N, Yu E, Yip B, Zalunardo N, Werb R, Hogg R, Harrigan PR, Montaner JS.
    Antivir Ther; 2006 Aug 28; 11(1):79-86. PubMed ID: 16518963
    [Abstract] [Full Text] [Related]

  • 19. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.
    Gallant JE, Parish MA, Keruly JC, Moore RD.
    Clin Infect Dis; 2005 Apr 15; 40(8):1194-8. PubMed ID: 15791522
    [Abstract] [Full Text] [Related]

  • 20. CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related.
    Kakuda TN, Anderson PL, Becker SL.
    AIDS; 2004 Dec 03; 18(18):2442-4. PubMed ID: 15622326
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.